Archived Seminar: Sex, Drugs and Radiomics of Brain Cancer
Pioneers in Biomedical Research Seminar presented by the Fralin Biomedical Research Institute at VTC
About this Seminar
Glioblastoma are notoriously aggressive, malignant primary brain tumors that have variable response to treatment. This presentation will focus on the integrative role of 1) biological sex-differences, 2) heterogeneity in drug-delivery and 3) intra-tumoral molecular diversity (revealed by radiomics) in capturing and predicting this variable response to treatment. Specifically, Dr. Swanson will highlight burgeoning insights into sex differences in tumor incidence, outcomes, propensity and response to therapy. She will further quantify the degree to which heterogeneity in drug delivery, even for drugs that are able to bypass the blood-brain barrier, contributes to differences in treatment response. Lastly, she will propose an integrative role for spatially resolved MRI-based radiomics models to reveal the intra-tumoral biological heterogeneity that can be used to guide treatment targeting and management.
This is a free event hosted by the Fralin Biomedical Research Institute and co-sponsored by the institute's Cancer Research Group. The Fralin Biomedical Research Institute Pioneers in Biomedical Research Program offers the expertise of a range of scientists who are exploring frontiers in biomedical research. These seminars are open to Virginia Tech and Carilion Clinic faculty, students, and staff.
You May Also Be Interested In...
Kristin R. Swanson, Ph.D.
The Vasek and Anna Maria Polak Professor in Cancer Research; Professor of Neurological Surgery, Molecular Neuroscience, and Radiation Oncology; Mayo Clinic, Phoenix, Arizona